Pendal Group’s Maravai LifeSciences MRVI Stock Holding History

Pendal Group’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$194K	Sell	13,543 -6,241	-32%	-$98.3K	﹤0.01%	482
2022 Q3	$505K	Sell	19,784 -46,257	-70%	-$1.16M	﹤0.01%	344
2022 Q2	$1.88M	Buy	66,041 +12,073	+22%	+$382K	0.02%	215
2022 Q1	$1.9M	Buy	53,968 +35,330	+190%	+$1.18M	0.02%	263
2021 Q4	$781K	Sell	18,638 -29,798	-62%	-$1.21M	0.01%	369
2021 Q3	$2.38M	Sell	48,436 -4,651	-9%	-$227K	0.02%	209
2021 Q2	$2.21M	Buy	53,087 +43,885	+477%	+$1.7M	0.02%	234
2021 Q1	$328K	Buy	+9,202	New	+$305K	﹤0.01%	468

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Pendal Group's MRVI Position: Q4 2022 in Review

Pendal Group reduced its Maravai LifeSciences (MRVI) stake by 32% in Q4 2022, selling an estimated $98.3K and leaving 13,543 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #482.

Pendal Group first reported a position in MRVI in Q1 2021 and has held it in 8 quarters since. The position peaked at $2.38M in Q3 2021. 212 funds tracked by Wall St. Rank hold MRVI as of Q4 2022.

Pendal Group held 13,543 shares of Maravai LifeSciences worth $194K as of Q4 2022.
Pendal Group sold 6,241 Maravai LifeSciences shares in Q4 2022, an estimated $98.3K.
Maravai LifeSciences made up ﹤0.01% of Pendal Group's portfolio in Q4 2022, its #482 holding.
Pendal Group first reported a position in Maravai LifeSciences in Q1 2021 and has held it in 8 quarters since.
Pendal Group's Maravai LifeSciences position peaked at $2.38M in Q3 2021.
212 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2022.

Based on Pendal Group's 13F filing for Q4 2022, filed 19 Jan 2023.